专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5028603A Ester-substituted thienotriazolodiazepine compounds and pharmaceutical uses thereof 失效
标题翻译：酯取代的噻吩并三唑并噻嗪类化合物及其药物用途
公开(公告)号：US5028603A
公开(公告)日：1991-07-02
申请号：US350589
申请日：1989-02-03
申请人： Tetsuya Tahara , Minoru Moriwaki , Masao Abe , Michio Terasawa
发明人： Tetsuya Tahara , Minoru Moriwaki , Masao Abe , Michio Terasawa
IPC分类号： A61K31/55 , A61P7/02 , A61P9/00 , A61P11/00 , A61P29/00 , A61P37/08 , C07D495/14
CPC分类号： C07D495/14
摘要： There are provided novel ester-substituted thienotriazolodiazepines useful for the treatment of various PAF-induced diseases.

2. 发明授权

US4937240A Thienotriazolodiazepine compounds and pharmaceutical uses thereof 失效
公开(公告)号：US4937240A
公开(公告)日：1990-06-26
申请号：US302874
申请日：1989-01-30
申请人： Minoru Moriwaki , Hiroshi Tanaka , Michio Terasawa , Tetsuya Tahara
发明人： Minoru Moriwaki , Hiroshi Tanaka , Michio Terasawa , Tetsuya Tahara
IPC分类号： C07D495/14
CPC分类号： C07D495/14
摘要： A thienotriazolodiazepine compound of the formula: ##STR1## wherein each symbol is as defined in the specification or a pharmaceutically acceptable salt thereof, and pharmaceutical uses thereof.Said compounds exhibit PAF-antagonistic activity and are useful for the prevention or treatment of various PAF-induced diseases.

3. 发明授权

US4960770A 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof 失效
标题翻译： 2-三烷基噻吩并（三唑并）二氮杂化合物及其药物用途
公开(公告)号：US4960770A
公开(公告)日：1990-10-02
申请号：US304989
申请日：1989-01-11
申请人： Minoru Moriwaki , Masao Abe , Hiroshi Mikashima , Tetsuya Tahara
发明人： Minoru Moriwaki , Masao Abe , Hiroshi Mikashima , Tetsuya Tahara
IPC分类号： A61K31/55 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , C07D495/04 , C07D495/14
CPC分类号： C07D495/04 , C07D495/14
摘要： A thienotriazolodiazepine compound of the formula: ##STR1## wherein Ar is phenyl, pyridyl, substituted phenyl or substituted pyridyl; R.sup.1 and R.sup.3 are the same or different and each is hydrogen, alkyl having 1 to 4 carbon atoms; R.sup.2 is hydrogen, alkyl having 1 to 4 carbon atoms or trifluoromethyl; R.sup.4 is straight or branched chain alkyl, alkenyl or alkynyl having 6 to 18 carbon atoms, or a thienodiazepine compound of the formula: ##STR2## wherein Ar, R.sup.1, R.sup.2 and R.sup.4 are as defined above, and pharmaceutically acceptable acid addition salt thereof.These compounds are useful as drugs for the treatment of circulatory diseases and various PAF-induced diseases. The compound (II) is also useful as an intermediate for preparing the compound (I).

4. 发明授权

US4820703A PAF-antagonistic thienotriazolodiazepine compounds and pharmaceutical uses thereof 失效
标题翻译： PAF拮抗性噻吩并三唑并噻嗪类化合物及其药物用途
公开(公告)号：US4820703A
公开(公告)日：1989-04-11
申请号：US121834
申请日：1987-11-17
申请人： Tetsuya Tahara , Minoru Moriwaki , Masao Abe , Shuji Yuasa
发明人： Tetsuya Tahara , Minoru Moriwaki , Masao Abe , Shuji Yuasa
IPC分类号： C07D495/14 , C07D495/12 , A61K31/55 , C07D495/04
CPC分类号： C07D495/14
摘要： A thienotriazolodiazepine compound of the formula: ##STR1## wherein A is alkylene or substituted alkylene and each other symbol is as defined in the specification and a pharmaceutically acceptable acid addition salt thereof, and pharmaceutical uses thereof.Said compounds exhibit PAF-antagonistic activity and are useful for the prevention or treatment of various PAF-induced diseases.

5. 发明授权

US5686479A Immunosuppressive drug 失效
标题翻译：免疫抑制药
公开(公告)号：US5686479A
公开(公告)日：1997-11-11
申请号：US244811
申请日：1994-06-10
申请人： Takeki Okumoto , Kenji Chiba , Yukio Hoshino , Hirotsugu Komatsu , Mariko Nagasawa , Hidekazu Aratani , Michio Terasawa , Minoru Moriwaki
发明人： Takeki Okumoto , Kenji Chiba , Yukio Hoshino , Hirotsugu Komatsu , Mariko Nagasawa , Hidekazu Aratani , Michio Terasawa , Minoru Moriwaki
IPC分类号： A61K31/55 , C07D495/14 , C07D495/22 , A61K31/41
CPC分类号： C07D495/14 , A61K31/55
摘要： An immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor, each containing a thienotriazolodiazepine compound wherein the 2-position of its diazepine ring is alkylated as an active ingredient, an immunosuppression method, an autoimmune disease treating method, an immunosuppression enhancing method and a cell adhesion inhibiting method, each of which comprising administering the compound, and uses of the compound for the production of an immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor.
摘要翻译： PCT No.PCT / JP92 / 01619 Sec。 371日期：1994年6月10日 102（e）日期1994年6月10日PCT提交1992年12月10日PCT公布。公开号WO93 / 12117 日期：1993年6月24日免疫抑制药物，自身免疫疾病治疗药物，免疫抑制增强药物和细胞粘附抑制剂，其各自含有噻吩并三氮杂环庚烯化合物，其中二氮杂环的2位被烷基化为活性成分，免疫抑制法，一种自身免疫疾病治疗方法，免疫抑制增强方法和细胞粘附抑制方法，其包括施用该化合物，以及该化合物用于制备免疫抑制药物，自身免疫疾病治疗药物，免疫抑制增强药物和细胞粘附抑制剂。

6. 发明授权

US5286858A Optically active thienotriazolodiazepine compounds 失效
标题翻译：光学活性噻吩并三唑并噻嗪化合物
公开(公告)号：US5286858A
公开(公告)日：1994-02-15
申请号：US774945
申请日：1991-10-11
申请人： Minoru Moriwaki , Syuji Yuasa , Hiroyuki Kitani , Michio Terasawa
发明人： Minoru Moriwaki , Syuji Yuasa , Hiroyuki Kitani , Michio Terasawa
IPC分类号： A61K31/55 , A61K31/00 , A61K31/554 , A61P7/02 , A61P9/00 , A61P11/00 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D495/14 , C07D495/12
CPC分类号： C07D495/14
摘要： Stable crystals of an acid addition salt of an optically active thienotriazolodiazepine compound or its hydrate of the formula ##STR1## wherein R.sup.1 is hydrogen, R.sup.2 is 2-phenylethyl substituted by alkyl having 1 to 5 carbon atoms, 2-morpholinocarbonylethyl or alkyl having 6 to 12 carbon atoms, or R.sup.1 and R.sup.2 may combinedly form a saturated 5-membered ring having one substituent selected from the group consisting of morpholinomethyl, morpholinocarbonyl and N,N-dipropylcarbamoyl, R.sup.3 is halogen, alkyl having 1 to 5 carbon atoms or alkoxy having 1 to 5 carbon atoms, R.sup.4 is trifluoromethyl or alkyl having 1 to 5 carbon atoms, R.sup.5 is hydrogen or methyl, m is 1-2, and n is 0-2. The present invention provides optically active thienotriazolodiazepine compounds having strong PAF-antagonistic activity as markedly stable crystals which are excellent in crystalline property, permit purification by recrystallization, and have high chemical purity and optical purity, thereby rendering industrial large-scale synthesis attainable. In addition, crystallization thereof facilitates medicinal standardization and pharmaceutical formulation.
摘要翻译：光学活性噻吩并三唑并噻嗪类化合物或其水合物（*化学结构*）（I）的酸加成盐的稳定晶体，其中R 1为氢，R 2为被具有1至5个碳原子的烷基取代的2-苯乙基，吗啉代羰基乙基或具有6至12个碳原子的烷基，或者R 1和R 2可以组合形成具有一个选自吗啉代甲基，吗啉代羰基和N，N-二丙基氨基甲酰基的一个取代基的饱和五元环，R 3是卤素， 5个碳原子或具有1至5个碳原子的烷氧基，R4是三氟甲基或具有1-5个碳原子的烷基，R5是氢或甲基，m是1-2，n是0-2。本发明提供具有优异结晶性的显色稳定结晶的具有强PAF拮抗作用的光学活性噻吩并三唑并氮杂化合物，可以通过重结晶进行纯化，化学纯度高，光学纯度高，从而可实现工业化的大规模合成。此外，其结晶有助于药物标准化和药物制剂。

7. 发明授权

US5593988A Therapeutic agent for osteoporosis and diazepine compound 失效
标题翻译：骨质疏松症和二氮杂化合物治疗剂
公开(公告)号：US5593988A
公开(公告)日：1997-01-14
申请号：US211572
申请日：1994-08-02
申请人： Tetsuya Tahara , Minoru Moriwaki , Kenji Chiba , Shunichi Manabe , Masanori Shindo , Takashi Nakagawa , Takeshi Nakamura
发明人： Tetsuya Tahara , Minoru Moriwaki , Kenji Chiba , Shunichi Manabe , Masanori Shindo , Takashi Nakagawa , Takeshi Nakamura
IPC分类号： C07D487/04 , C07D495/04 , C07D495/14 , C07D498/04 , C07D498/14 , C07D498/22 , C07D513/04 , C07D513/14 , A61K31/55
CPC分类号： C07D487/04 , C07D495/04 , C07D495/14 , C07D513/04 , C07D513/14
摘要： A therapeutic agent for osteoporosis, comprising an azepine compound of the formula ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.
摘要翻译： PCT No.PCT / JP92 / 01325 Sec。 371日期1994年8月2日 102（e）日期1994年8月2日PCT提交1992年10月12日PCT公布。公开号WO93 / 07129 日期：1993年04月15日，一种用于骨质疏松症的治疗剂，其包含式（I）的吖庚因化合物，其中每个符号如说明书中所定义，或其药学上可接受的盐作为活性成分，治疗骨质疏松症的方法包括施用所述化合物和所述化合物用于产生骨质疏松症治疗剂的用途。式（I）的化合物具有优异的骨吸收抑制活性，并且用于减少由骨吸收引起的血清中钙的增加量。因此，这些化合物可用作药物，以有效抑制骨吸收，防止骨质量的降低，防止或抑制由于骨吸收进程引起的血液中钙量的增加，关于佩吉特氏病，高钙血症，骨质疏松症等，其中骨吸收的进展被认为与症状密切相关，以及骨吸收进展（发展为骨质疏松症）以及类风湿性关节炎等炎症性关节疾病的症状。

8. 发明授权

US5753649A Therapeutic agent for osteoporosis and diazepine compound 失效
标题翻译：骨质疏松症和二氮杂化合物治疗剂
公开(公告)号：US5753649A
公开(公告)日：1998-05-19
申请号：US706350
申请日：1996-08-30
申请人： Tetsuya Tahara , Minoru Moriwaki , Kenji Chiba , Shunichi Manabe , Masanori Shindo , Takashi Nakagawa , Takeshi Nakamura
发明人： Tetsuya Tahara , Minoru Moriwaki , Kenji Chiba , Shunichi Manabe , Masanori Shindo , Takashi Nakagawa , Takeshi Nakamura
IPC分类号： C07D487/04 , C07D495/04 , C07D495/14 , C07D498/04 , C07D498/14 , C07D498/22 , C07D513/04 , C07D513/14 , A61K31/55
CPC分类号： C07D487/04 , C07D495/04 , C07D495/14 , C07D513/04 , C07D513/14
摘要： A therapeutic agent for osteoporosis, comprising an azepine compound of the formula ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.
摘要翻译：一种骨质疏松症治疗剂，其包含式（I）的吖庚因化合物，其中每个符号如说明书中所定义，或其药学上可接受的盐作为活性成分，治疗骨质疏松症的方法，包括给予所述化合物和所述化合物用于制备骨质疏松症治疗剂的用途。式（I）的化合物具有优异的骨吸收抑制活性，并且用于减少由骨吸收引起的血清中钙的增加量。因此，这些化合物可用作药物，以有效抑制骨吸收，防止骨质量的降低，防止或抑制由于骨吸收进程引起的血液中钙量的增加，关于佩吉特氏病，高钙血症，骨质疏松症等，其中骨吸收的进展被认为与症状密切相关，以及骨吸收进展（发展为骨质疏松症）以及类风湿性关节炎等炎症性关节疾病的症状。

9. 发明授权

US09519178B2 Color filter substrate, electro-optic device, and electronic apparatus 有权
标题翻译：彩色滤光片基板，电光器件和电子设备
公开(公告)号：US09519178B2
公开(公告)日：2016-12-13
申请号：US13446076
申请日：2012-04-13
申请人： Minoru Moriwaki
发明人： Minoru Moriwaki
IPC分类号： G02F1/1335 , G02B5/20
CPC分类号： G02F1/133512 , G02B5/201 , G02F1/133553 , G02F2203/02
摘要： A color filter substrate includes a color filter layer, a light-transmissive layer and a light-shielding layer. The light-transmissive layer is disposed between pixels and includes a side surface that forms a reflection surface. The light-shielding layer is laminated on the light-transmissive layer.
摘要翻译：滤色器基板包括滤色器层，透光层和遮光层。透光层设置在像素之间并且包括形成反射表面的侧表面。遮光层层叠在透光层上。

10. 发明申请

US20110249227A1 ELECTRO-OPTICAL DEVICE AND ELECTRONIC APPARATUS 有权
标题翻译：电光设备和电子设备
公开(公告)号：US20110249227A1
公开(公告)日：2011-10-13
申请号：US13083933
申请日：2011-04-11
申请人： Minoru Moriwaki , Hiroaki Mochizuki
发明人： Minoru Moriwaki , Hiroaki Mochizuki
IPC分类号： G02F1/1343
CPC分类号： G02F1/136213 , G02F1/136227 , G02F1/136286
摘要： In at least one embodiment of the disclosure, an electro-optical device comprises a pixel electrode and a transistor corresponding to the pixel electrode. A data line is electrically connected to the transistor. A storage capacitor is provided between the pixel electrode and the transistor. The storage capacitor has a first capacitance electrode and a second capacitance electrode facing each other. A capacitance isolation film is interposed therebetween. An additional capacitor is electrically connected to the data line. The additional capacitor has a first additional capacitance electrode and a second additional capacitance electrode facing each other. An additional capacitance isolation film is interposed therebetween. The first additional capacitance electrode is provided on a same layer as the first capacitance electrode. The second additional capacitance electrode is provided on a layer different from the layers of the first and second capacitance electrodes.
摘要翻译：在本公开的至少一个实施例中，电光装置包括像素电极和对应于像素电极的晶体管。数据线电连接到晶体管。在像素电极和晶体管之间提供存储电容器。存储电容器具有彼此面对的第一电容电极和第二电容电极。插入电容隔离膜。附加的电容器电连接到数据线。附加电容器具有彼此面对的第一附加电容电极和第二附加电容电极。在其间插入附加的电容隔离膜。第一附加电容电极设置在与第一电容电极相同的层上。第二附加电容电极设置在与第一和第二电容电极的层不同的层上。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式